CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 527 enrolled
Drug / intervention
DEXYCU (dexamethasone intraocular suspension) 9%.drug
Likely dose
DEXYCU (dexamethasone intraocular suspension) 9%. 103.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04290676
NCT04290676N/ACompleted
CompareCT.gov

DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

EyePoint Pharmaceuticals, Inc.·observational·Posted Mar 2, 2020·Updated May 26, 2021

In Brief

An observational study evaluating DEXYCU (dexamethasone intraocular suspension) 9%. for Cataract. Completed, enrolled 527 participants across 22 sites.

Detailed Summary

Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMar 2, 2020
Enrollment StartNov 13, 2019
Primary CompletionMay 1, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.3 years ago

Interventions

DEXYCU (dexamethasone intraocular suspension) 9%.drug

DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).